Aranesp Company Profile

11:52 EST 14th December 2018 | BioPortfolio

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.
Important Product Safety Information

Aranesp® is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of thrombotic events and other serious events. Seizures have occurred in patients with CRF. The target hemoglobin (Hb) should not exceed 12 g/dL. If the Hb increase exceeds 1.0 g/dL in any 2-week period, dose reductions are recommended. In a study of Epoetin alfa treated hemodialysis patients with clinically evident cardiac disease, where the target hematocrit (Hct) was 42% (Hb = 14 g/dL), an increased incidence of thrombotic events and mortality was seen. The reason for increased mortality observed in this study is unknown. In a study with another erythropoietic product, in women with metastatic breast cancer receiving chemotherapy, where the target Hb was 12-14 g/dL, an increased incidence of thrombotic events, disease progression, and mortality was seen

News Articles [3 Associated News Articles listed on BioPortfolio]

Human medicines European public assessment report (EPAR): Aranesp, darbepoetin alfa, Revision: 40, Authorised

PTV News: Nov 3, 2009

Top stories on November 3rd, 2009: Novartis invests US$ 1B in China R&D plant Anaemia drugs: Amgen's Aranesp doubles stroke risk Teva Q3: Net Sales up 25% Roches partnering vision:  Dan Zabrowski...

Step Therapy For Anti-Inflammatories, ESAs Coming To UnitedHealthcare Medicare Plans

Remicade, Procrit, Aranesp and biosimilars will be subject to step therapy in limited number of Medicare Advantage plans in 2019.   

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Aranesp [AMGEN INC]

These highlights do not include all the information needed to use Aranesp safely and effectively. See full prescribing information for Aranesp. Aranesp(darbepoetin alfa)injection, for intravenous or s...

Aranesp [Physicians Total Care, Inc.]

PubMed Articles [0 Results]


Clinical Trials [29 Associated Clinical Trials listed on BioPortfolio]

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

The purpose of this study was to evaluate Aranesp® administered subcutaneously (SC) to maintain hemoglobin (Hb) levels in renal transplant recipients.

Study to Evaluate Effectiveness of Aranesp®

The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).

A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

The purpose of this trial is to assess the effectiveness of Aranesp® administered at 300 mcg every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and mai...

A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving ...

Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability and Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

BCD-066 is a darbepoetin alfa. Clinical study BCD-066-3 is a double-blind controlled, randomized, parallel-group study of the pharmacokinetics, pharmacodynamics, tolerability, and safety o...

Companies [2 Associated Companies listed on BioPortfolio]

Aranesp® (darbepoetin alfa)

Aranesp® (darbepoetin alfa) is approved for the treatment of anemia associated with chronic kidney disease and chemotherapy.


Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of...

More Information about "Aranesp" on BioPortfolio

We have published hundreds of Aranesp news stories on BioPortfolio along with dozens of Aranesp Clinical Trials and PubMed Articles about Aranesp for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aranesp Companies in our database. You can also find out about relevant Aranesp Drugs and Medications on this site too.

Quick Search


Relevant Topics

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...

Corporate Database Quicklinks

Searches Linking to this Company Record